VIFOR-PHARMA
14.12.2021 06:46:07 CET | Business Wire | Press release
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, today announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion.
CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 (CHF 167) per share, payable in U.S. dollars.1 The offer assumes a dividend of CHF 2 expected to be declared at the AGM of 26 April, consistent with past practice.
The tender offer represents an implied premium of approximately 61% to the unaffected closing price of Vifor Pharma on 1 December 2021 and a 47% premium to Vifor Pharma’s unaffected 1-month VWAP as of 1 December 2021.2
Patinex AG, Vifor Pharma’s largest shareholder holding 23.2% has agreed to tender its shares into the offer.
The Transaction remains subject to the conditions and further terms including:
- Minimum acceptance rate of 80% of all Vifor Pharma shares on a fully diluted basis; and
- further customary offer conditions, including regulatory approvals.
The tender is currently expected to commence around 18 January 2022 and the transaction is expected to complete around mid-2022.
The Board of Directors of Vifor Pharma considers that the proposed transaction respects the interests of all stakeholders and is unanimously recommending the offer to shareholders. There is committed financing for the deal and a strong commitment to pursue regulatory clearances.
“Vifor Pharma's strategy has been to focus towards continuing being a market leader in iron deficiency, nephrology and cardio-renal therapies.” Jacques Theurillat, Chairman of the Board of Directors Vifor Pharma Group commented. “The offer provides an excellent strategic opportunity for Vifor Pharma to optimize future market opportunities from a position of strength and to create substantial value for all stakeholders.”
The transaction will enable Vifor Pharma to leverage CSL’s global reach, balance sheet and capabilities to bring more products to patients within its key categories. The transaction also enables Vifor Pharma to accelerate growth in cardiovascular-metabolic, renal and transplant.
Centerview Partners UK LLP is acting as exclusive financial advisor to Vifor Pharma on the transaction.
IFBC have been retained as Fairness Opinion providers by the Vifor Pharma Board of Directors.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About CSL
CSL (ASX: CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus- provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information visit csl.com.
Legal Disclaimers
Important Additional Information
The tender offer described herein has not yet commenced. This release is for informational purposes only and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any registered shares or other equity securities in Vifor Pharma Ltd., nor shall it form the basis of, or be relied on in connection with, any contract therefor. This release is not part of the offer documentation relating to the tender offer. Main terms and conditions of the tender offer have been published in today's Pre-Announcement of the tender offer, and full details including terms and conditions will be published in the tender offer prospectus. Shareholders of Vifor Pharma Ltd. are urged to read the tender offer documents, which are or will be available at www.CSLtransaction.com .
Certain Offer Restrictions
Reference is made to the Pre-Announcement of the tender offer published today for full offer restrictions.
1 At USD to CHF FX rate of 0.932.
2 Based on the last closing price of Vifor Pharma prior to public speculation regarding a potential transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213006121/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights5.8.2026 12:30:00 CEST | Press release
Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to be a blockbuster opportunity, if approved Rolling NDA submission and initial review underway and final submission expected to be completed in Q4 Commercial launch expected in first half of 2027 COMP360 expected to fit seamlessly into current treatment infrastructure Late-stage PTSD trial underway Strong cash position of $433 million at the end of second quarter, providing cash well beyond launch and into 2028 Compass management will host a conference call on August 5 at 8:00 am ET Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 financial results and business highlights
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates5.8.2026 12:00:00 CEST | Press release
Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior yearDiluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarterRaised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong second-quarter results underscore our continued growth as a global oncology leader. Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry’s deepest and most
Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 20265.8.2026 11:11:00 CEST | Press release
Tecnotree, a global leader in AI-native Digital Business Support Systems (BSS) and digital platform solutions for the telecommunications industry, today announced its financial results for the first half of 2026. The company delivered growth across every principal financial measure, expanded operating margin by 800 basis points, and converted a record order book into deployment at pace, with eight go-lives completed across the North America, Africa and the Middle East. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805406933/en/ Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 2026 First Half (January – June 2026) Net sales of EUR 36.8 million (EUR 34.2 million), up 7.5% year-on-year; in constant currency, EUR 37.6 million, up 10.0% year-on-year. Operating result (EBIT) of EUR 13.2 million (EUR 9.6 million), up 38.1% year-on-year. Operating margin of 36.0% (28.0%), up 800 bps year-on
Ekovolt Welcomes Éric Scotto, Co-Founder of Akuo Energy, as a Shareholder, and Rebrands as Pont Digital Infrastructure5.8.2026 10:00:00 CEST | Press release
Ekovolt, a holding company focused on the development and investment in next-generation data centre infrastructure, and co-owner of Voltekko, a Southern European data centre development platform, today announces two milestones: Éric Scotto — co-founder and former President of Akuo Energy, a pioneering figure in the French and international energy transition — becoming a shareholder, and the company’s rebranding as Pont Digital Infrastructure. Éric Scotto, an iconic figure in French renewable energy, joins the company as a shareholder, bringing recognised expertise in developing, financing and structuring long-term sustainable infrastructure projects. After an early career in information technology and finance, Éric Scotto moved into renewable energy in 2003. He founded Perfect Wind and developed one of the first large-scale wind farms in France (57 MW) in partnership with General Electric — with operations also in Poland and Turkey — before selling the company to Iberdrola in 2006. In
Bending Spoons opens office in Madrid, betting on a promising pool of tech talent5.8.2026 09:00:00 CEST | Press release
Bending Spoons, the technology company behind products such as WeTransfer and Meetup, has opened an office in Madrid. The decision is underpinned by Spain’s strong talent pool, fuelled by excellent universities, and by Madrid’s international appeal and its quality of life. “We’re impressed by the talent we’ve seen in Spain. This year, we’ve received around 10,000 Spain-based applicants every month, and many of them perform among the very best candidates in our selection process. The calibre of education offered by Spanish universities is particularly high, and over the next few years we’re hoping to grow our team in Madrid into the hundreds,” says Andrea Maiorana, talent data lead. Located in the Recoletos area, the office is the company’s third European base, following the Milan headquarters and the recently opened London branch. The office is in one of the city's most coveted locations, within walking distance of Retiro Park and the Prado Museum. For new hires relocating to Madrid, B
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom